MA25562A1 - Procede pour administrer un inhibiteur de phosphodiesterase 4. - Google Patents

Procede pour administrer un inhibiteur de phosphodiesterase 4.

Info

Publication number
MA25562A1
MA25562A1 MA26618A MA26618A MA25562A1 MA 25562 A1 MA25562 A1 MA 25562A1 MA 26618 A MA26618 A MA 26618A MA 26618 A MA26618 A MA 26618A MA 25562 A1 MA25562 A1 MA 25562A1
Authority
MA
Morocco
Prior art keywords
phosphodiesterase
administering
inhibitor
Prior art date
Application number
MA26618A
Other languages
English (en)
Inventor
J Torphy Theodore
D Zussman Barry
D Murdoch Robert
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp
Publication of MA25562A1 publication Critical patent/MA25562A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
MA26618A 1999-10-29 2002-04-26 Procede pour administrer un inhibiteur de phosphodiesterase 4. MA25562A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16247799P 1999-10-29 1999-10-29
US16264199P 1999-11-01 1999-11-01
US17981700P 2000-02-02 2000-02-02

Publications (1)

Publication Number Publication Date
MA25562A1 true MA25562A1 (fr) 2002-10-01

Family

ID=27388757

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26618A MA25562A1 (fr) 1999-10-29 2002-04-26 Procede pour administrer un inhibiteur de phosphodiesterase 4.

Country Status (29)

Country Link
US (1) US20030212112A1 (fr)
EP (1) EP1225884A4 (fr)
JP (1) JP2003513038A (fr)
KR (1) KR20020050249A (fr)
CN (1) CN1387433A (fr)
AP (1) AP2002002446A0 (fr)
AR (1) AR026254A1 (fr)
AU (1) AU772909B2 (fr)
BG (1) BG106623A (fr)
BR (1) BR0015039A (fr)
CA (1) CA2389293A1 (fr)
CO (1) CO5271676A1 (fr)
CZ (1) CZ20021443A3 (fr)
DZ (1) DZ3249A1 (fr)
EA (1) EA200200502A1 (fr)
HK (1) HK1049105A1 (fr)
HU (1) HUP0203682A3 (fr)
IL (1) IL148813A0 (fr)
MA (1) MA25562A1 (fr)
MX (1) MXPA02004220A (fr)
NO (1) NO20021937L (fr)
NZ (1) NZ518002A (fr)
OA (1) OA12078A (fr)
PE (1) PE20011004A1 (fr)
PL (1) PL355262A1 (fr)
SK (1) SK7292002A3 (fr)
TR (1) TR200201150T2 (fr)
UY (1) UY26422A1 (fr)
WO (1) WO2001032165A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR029984A1 (es) * 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
DE10207160A1 (de) * 2002-02-20 2003-12-18 Altana Pharma Ag Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US20060084684A1 (en) * 2002-05-28 2006-04-20 Altana Pharma Ag Topically applicable pharmaceutical preparation
US6822114B1 (en) 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
EA009985B1 (ru) 2003-03-10 2008-04-28 Никомед Гмбх Новый способ получения рофлумиласта
WO2004096274A1 (fr) * 2003-03-31 2004-11-11 Kyowa Hakko Kogyo Co., Ltd. Medicament administre par voie orale
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
ES2421916T3 (es) 2005-03-16 2013-09-06 Nycomed Gmbh Forma farmacéutica de sabor enmascarado que contiene roflumilast
KR101763440B1 (ko) * 2009-12-03 2017-08-14 옵코 헬스, 인크. 과황산화 이당 제제
AU2012362562B2 (en) * 2011-12-27 2017-11-02 Amgen (Europe) GmbH Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
CN103536582A (zh) * 2013-10-12 2014-01-29 云南龙海天然植物药业有限公司 罗氟司特干粉吸入剂
WO2019147824A1 (fr) 2018-01-26 2019-08-01 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur de pde4
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
MY121142A (en) * 1999-02-23 2005-12-30 Smithkline Beecham Corp Controlled release formulation for treating copd
AR035987A1 (es) * 1999-03-01 2004-08-04 Smithkline Beecham Corp Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio

Also Published As

Publication number Publication date
BR0015039A (pt) 2002-06-25
EA200200502A1 (ru) 2002-10-31
CZ20021443A3 (cs) 2003-01-15
OA12078A (en) 2003-05-28
NZ518002A (en) 2004-01-30
PL355262A1 (en) 2004-04-05
SK7292002A3 (en) 2002-12-03
EP1225884A1 (fr) 2002-07-31
IL148813A0 (en) 2002-09-12
AU1344501A (en) 2001-05-14
EP1225884A4 (fr) 2005-06-15
HUP0203682A2 (hu) 2003-04-28
NO20021937L (no) 2002-05-30
AU772909B2 (en) 2004-05-13
AP2002002446A0 (en) 2002-03-31
JP2003513038A (ja) 2003-04-08
TR200201150T2 (tr) 2002-09-23
HUP0203682A3 (en) 2003-10-28
UY26422A1 (es) 2001-07-31
CO5271676A1 (es) 2003-04-30
PE20011004A1 (es) 2001-09-28
DZ3249A1 (fr) 2001-05-10
NO20021937D0 (no) 2002-04-24
WO2001032165A1 (fr) 2001-05-10
CN1387433A (zh) 2002-12-25
US20030212112A1 (en) 2003-11-13
AR026254A1 (es) 2003-02-05
BG106623A (bg) 2003-02-28
CA2389293A1 (fr) 2001-05-10
KR20020050249A (ko) 2002-06-26
HK1049105A1 (zh) 2003-05-02
MXPA02004220A (es) 2002-10-17

Similar Documents

Publication Publication Date Title
ZA200109890B (en) Metalloprotease inhibitors.
ZA200108735B (en) Renin inhibitors.
EP0685658A3 (fr) Dispositif de retenue pour un écrou.
ZA200006577B (en) Phthalazine derivatives as phosphodiesterase 4 inhibitors.
ZA200006116B (en) Distillation process for easily polymerizable substance-containing solution.
MA26250A1 (fr) PROCEDE DE CONTRôLE D'UN DETECTEUR.
ZA977694B (en) Heterocyclic metalloprotease inhibitors.
ID28489A (id) Metode untuk membuat 4-karboksiamino-2-disubstitusi 1,2,3,4-tetrahidroquinolin
HUP0000536A2 (en) Method for levelling a track
ITGE20000114A0 (it) Dispositivo per l'agugliatura di un'ovatta.
FR2809260B1 (fr) Procede d'approvisionnement d'un compte prepaye
IL148813A0 (en) Method for administering a phosphodiesterase 4 inhibitor
ZA995444B (en) A method for the treatment of staphylococcal disease.
ZA200110053B (en) Factor via inhibitors.
ZA200108980B (en) Cold distillation method. Cold distillation method.
EP1237112A4 (fr) Procede de realisation de transactions securisees sur livret bancaire electronique (tirelire)
ITRM990744A0 (it) Metodo per l'istallazione di elevatori.
IT1317270B1 (it) Apparecchiatura a cambio di velocita' per un trattore.
FI19992315L (fi) Menetelmä hillon valmistamiseksi
FR2720409B1 (fr) Méthode pour détecter des composés antimicrobiens.
FR2795009B3 (fr) Procede pour raccorder des sections de raccordement
IT1316262B1 (it) Procedimento per il funzionamento di un autoveicolo.
IL141031A0 (en) New pharmaceutical uses for nos inhibitors
DE50015637D1 (de) Verfahren zu dessen ansteuerung
FR2833389B1 (fr) Systeme et procede visant a empecher le detournement d'avions.